BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

...few clinical readouts beyond the macrophage marker CD47.The...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...the purchase of 2.3 million shares at $10.88, which will fund clinical testing of Trillium’s CD47...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

...are chasing similar targets – such as CD47...
BioCentury | Sep 5, 2020
Deals

Deal with AbbVie, PIPE triples I-Mab’s cash, positions biotech to be among China’s CD47 leaders

...its cash position on Friday, adding more than $600 million to its coffers through a CD47...
...negotiation to license two CD47-related bispecific mAb programs: one targeting CD-47 and PD-L1, and another against CD47...
...Red blood cells also express CD47 to prevent their destruction by the immune system, and CD47...
BioCentury | Aug 18, 2020
Deals

Lilly’s global deal for Innovent PD-1 could lead to U.S. approval, adds more cash for biotech’s R&D

...Tyvyt. Among the others are IBI188, a mAb targeting CD47; IBI322, a bispecific antibody targeting CD47...
BioCentury | Jul 18, 2020
Finance

Biotech trio’s NASDAQ debuts push year’s IPO haul past $13B

...raising $161.5 million at a valuation of $669 million. ALX, which is developing immunotherapies targeting CD47...
BioCentury | Jul 16, 2020
Finance

Relay’s IPO among the year’s largest for a biotech as others wait in wings

...million at a valuation in the $550 million range. The company is developing immunotherapies targeting CD47...
BioCentury | Jul 14, 2020
Finance

Three biotechs step up to the IPO plate following Nkarta’s debut

...and be valued at $555.4 million. The company is developing ALX148, a fusion protein against CD47...
BioCentury | Jul 11, 2020
Translation in Brief

Peptide blocker of myeloid checkpoint; plus a magnet-based device to collect circulating tumor cells, severe vs. mild COVID-19 immune cell profiles and more

...reported in Cell Chemical Biology the development of a macrocyclic peptide that allosterically blocks the CD47-SIRPA...
...of lymphoma. Over 10 companies are developing inhibitors of the pathway; the most advanced is anti-CD47...
...Tyrosinase related protein 1 Danielle Kopke, Staff Writer Massachusetts General Hospital University of Colorado Anschutz Medical Campus Arca biopharma Inc. CD47 Signal...
BioCentury | Jun 30, 2020
Finance

June 29 Quick Takes: BioNTech pockets $250M; plus three biotechs join NASDAQ IPO queue

...series C led by Vivo Capital. The company is developing ALX148, a fusion protein against CD47...
Items per page:
1 - 10 of 136